Introduction {#Sec1}
============

Osteoporosis is a silent, asymptomatic disease affecting millions of older people of all ethnicities. The disease is disproportionately observed in women, and it is estimated that 200 million women worldwide have osteoporosis \[[@CR1]\]. The prevalence of osteoporosis in Europe in 2010 was estimated at 27.6 million, of which 22 million were women \[[@CR1], [@CR2]\]. Osteoporosis is associated to a high risk of low-energy fractures of the hip, spine, proximal humerus or forearm. This risk significantly increases with age, and approximately 90% of the fractures are sustained in patients aged 60 years and older \[[@CR3]\].

In the year 2000, there were an estimated 8.9 million new osteoporotic fractures worldwide, comprising 1.6 million hip fractures, 1.7 million forearm fractures and 1.4 million vertebral fractures. For these fractures, the female-to-male ratio was 1.6 \[[@CR4]\]. In the Western world, the lifetime risk of any fracture in women over the age of 50 years is in the order of 40--51% and for hip fracture is 18--23% \[[@CR5], [@CR6]\]. Hip fracture is the most severe type of fracture in osteoporotic patients. Its incidence is highly variable from country to country (\<100 to \>400 per 100,000 habitants), as well as is the age-related exponential increase with age \[[@CR7]\]. By 2050, the worldwide annual number of hip fractures is expected to reach 4.5 to 6.3 million, reflecting the continuous ageing of the population \[[@CR8], [@CR9]\].

Osteoporotic hip fractures represent a particularly high burden in economic costs as compared to other fracture sites \[[@CR2]\]. Hip fracture commonly leads to long-term physical disability, reducing quality of life and impairing the capacity to live independently and perform daily activities \[[@CR10]\]. The cascade of consequences associated with hip fractures also includes depression (that may result in slowed recovery), health co-morbidities and increased risk of death \[[@CR11]--[@CR16]\].

Following a hip fracture, all-cause mortality rates are higher within the first 3 months (5.75-fold higher in women and 7.95-fold higher in men compared to controls) \[[@CR17]\]. In observational studies across the USA and Europe, 8--36% of patients died within the first year \[[@CR18]--[@CR21]\], and the 5-year mortality risk in this population was evaluated at 64% \[[@CR22]\]. The 1-year morbidity rates after a hip fracture are higher in elderly patients suffering from depression, delirium or dementia, highlighting the need for personalised care \[[@CR23]\]. It is difficult to determine the proportion of deaths that are causally related to the hip fracture rather than due to morbidity, but indirect evidence from the pattern of mortality with time suggests that approximately 30% of deaths are a direct result of the fracture event \[[@CR24]\].

The burden of osteoporosis as evaluated by disability-adjusted life years (DALYs) in Europe and the Americas accounts for 2 million DALYs annually, which is more than those explained by hypertensive heart disease \[[@CR2]\]. In the USA, in 2005, osteoporosis-related hip fractures in men and women over the age of 50 cost nearly \$12.2 billion \[[@CR25]\]. The economic burden of incident and prior fragility fractures in the European Union was estimated at € 37 billion in 2010. Incident fractures represented 66% of this cost, long-term fracture care 29% and pharmacological prevention 5%. These costs are expected to increase by 25% in 2025 \[[@CR2]\].

Several tools have been developed to detect patients at increased risk of fracture. The FRAX assessment tool is widely used to evaluate the fracture risk in osteoporotic patients \[[@CR26]\]. This tool based on simple questions assessing bone mineral density (BMD)-independent risk factors provides 10-year probability of experiencing major osteoporotic fractures or specifically hip fracture. BMD at the femoral neck can optionally be entered to enhance fracture prediction.

Second hip fractures tend to occur early following an initial hip fracture. Annual incidence for a second hip fractures ranges from 2 to 10% with a mean interval between first and second hip fracture of approximately 2 years \[[@CR27]--[@CR29]\]. In hip fracture patients, the cumulative incidences for second hip fracture range between 2.4 and 5.1% within the first year, 5.1 and 8.1% within the first 2 years, 8.0 and 8.2% at 5 years and 8.6% within the first 8 years \[[@CR28], [@CR30]--[@CR32]\]. A retrospective study of 241 hip fractures also reported that 11% of the patients had previously experienced a contralateral hip fracture on average 5.6 years before \[[@CR33]\]. This risk of recurrent hip fracture persists for at least 10 years amongst hip fracture survivors, with a reported risk of 8% of a second fracture within 10 years \[[@CR34], [@CR35]\].

In this context, the benefits of coordinator-based systems to ensure appropriate management of patients following a fracture are well established \[[@CR36]--[@CR38]\]. The International Osteoporosis Foundation (IOF) has launched a global campaign ('*Capture the fracture* ^™^ ') to promote this approach for the prevention of a second fracture \[[@CR36]\]. This initiative aims to set internationally endorsed standards for best practice by facilitating the implementation of fracture liaison services (FLSs) involving best practice frameworks, multidisciplinary models and FLS questionnaires \[[@CR36]--[@CR38]\]. Despite the major burden associated with osteoporosis and fragility fracture and the antifracture efficacy of the available therapies, there is a marked treatment gap in osteoporosis, i.e. a significant proportion of patients at high fracture risk or those who have sustained a fragility fracture are not being treated \[[@CR1], [@CR2]\]. In Europe, the treatment gap for osteoporosis ranges from 63 to 80% according to country and gender \[[@CR1]\]. Only moderate usage of treatments like calcium and vitamin D (8--62%, median 18%) postfracture is seen. Bisphosphonate usage is lower (0.5--38%) \[[@CR39]\]. In patients who sustain a fragility fracture, it was reported that fewer than 20% of individuals receive therapies (about 5% in the case of a first hip fracture) \[[@CR40]\]. More recent data indicate that in Europe and the USA, less than 25 and 20%, respectively, of patients with a hip fracture receive osteoporosis medication, with less than 15% receiving bisphosphonates \[[@CR41]\].

These considerations highlight the need for appropriate management options, particularly in very high-risk osteoporotic patients. This review provides a critical analysis of currently available approaches to increase bone mass, structure and strength through drug therapy and of possible direct intra-osseous interventions for the management of patients at imminent risk of hip fracture.

Methods {#Sec2}
=======

Relevant articles and reviews were identified through PubMed/MEDLINE by working group members. Other items were selected from the reference lists of related articles and the presentations during the working group meeting.

Pathogenesis of osteoporotic fracture {#Sec3}
=====================================

A bone fracture occurs when the externally applied load exceeds its intrinsic load-bearing capacity. Thus, the resulting bone deformation initiates tissue damage, which results in a major crack through the bone structure (Fig. [1](#Fig1){ref-type="fig"}). Recent data from a prospective study where hip strength was estimated by finite element analyses (FEAs) actually demonstrates that virtually, all hip fractures occur in subjects whose hip strength is below 3000 N \[[@CR42]\]. Areal bone mineral density (aBMD), as measured by dual-energy X-ray absorptiometry (DXA), is the most commonly used surrogate of bone strength \[[@CR42]--[@CR45]\]. aBMD accounts for 60 to 80% of bone strength variance. However, bone strength also depends on bone geometry, microstructure and material properties \[[@CR46]--[@CR48]\]. It is therefore important to recognise that the annual percentage loss of hip strength exceeds the percentage loss of areal bone mineral density and this difference increases exponentially with age, emphasizing the importance of structural changes as a determinant of bone fragility \[[@CR49]\].Fig. 1Pathogenesis and overview of the management of the osteoporotic fracture

With the menopause and then ageing, early trabecular thinning and loss of connectivity occur, leading to a weakening of predominantly cancellous bone parts such as the vertebrae and ultradistal radius. At the latter site, for instance, a 20% loss of trabecular number or thickness have been estimated to cause a 10% loss of strength \[[@CR50]\]. However, even at the distal radius, the thin cortical shell (typically less than 1 mm) carries more than 50% of the load \[[@CR51]\], so that a 20% loss of cortical bone volume at that site would cause a 37% loss of strength \[[@CR50]\]. Hence, cortical thickness is a major contributor to bone strength; however, its importance varies according to the bone site and the mechanism of the fracture \[[@CR52], [@CR53]\]. Although there is evidence that part of the axial load carried by the cortical shell in the human vertebra increases with age \[[@CR54]\], the overall stiffness contribution of the cortical shell is almost balanced with that of the trabecular component alone \[[@CR55]\]. Cortical porosity increases with age and represents a major contribution of the decrease in bone material stiffness and toughness \[[@CR56]\]. Hence, with ageing, the cortical bone becomes substantially thinner, and more porous, leading to loss of elasticity and increased fracture risk in a region, which undergoes compression during a fall \[[@CR57], [@CR58]\]. At the hip, cortical thinning occurs asymmetrically with ageing, so that the percentage of bone loss is greater in the thinner superior cortex than in the thicker inferior portion \[[@CR59]\].

There is a shifting opinion regarding the origin of a hip fracture, particularly with respect to the initiation of failure in trabecular vs. cortical bone, and the importance of the trabecular network to contribute to hip strength. In the proximal femur, a study suggested that removing the trabecular core of the hip reduces by only 7% the all-hip strength in compression, which suggests a major contribution of cortical bone \[[@CR52]\]. However, this study has been heavily criticised because the fracture was produced in stance loading and not in a sideway fall loading. In the latter case scenario, fracture mechanisms as identified in cadaver bone appear to involve compression failure on the supero-lateral side (a region with little cortical bone) and tension failure on the medial side (rich in cortical bone) \[[@CR60]\]. But, trabecular bone has the ability to absorb some excess energy. In weakened, osteoporotic bones, increasing trabecular strength provides improved structural redundancy, thereby increasing the threshold for fracture initiation \[[@CR61]\]. Cortical bone appears only to be engaged in the failure process when there is insufficient trabecular strength in the trochanteric and subcapital femoral neck regions to withstand the fall loading \[[@CR61]\]. Once the cortex gets involved, tissue-level failure appears in both bone compartments, with equal contribution.

Therefore, in designing new approaches to restore bone strength of the hip, both compartments should be considered for reinforcement.

Current management options {#Sec4}
==========================

Non-pharmacological options {#Sec5}
---------------------------

Preventive measures include lifestyle interventions, fall prevention and possibly the use of hip protectors (Fig. [2](#Fig2){ref-type="fig"}). Hip pads are an example of such an approach, as they aim to reduce to the amount of mechanical energy transmitted to the hip following a fall, with the hope that this will reduce the likelihood of fracture. The effectiveness of this intervention is controversial and also limited by poor compliance and acceptance \[[@CR63]--[@CR65]\].Fig. 2The fracture prevention triangle \[[@CR62]\]. Adapted from Cryer C, Patel S. Falls, fragility and fractures. National service framework for older people. The case for and strategies to implement a joint health improvement and modernisation plan for falls and osteoporosis. London: Alliance for Better Bone Health, 2001

Non-pharmacological interventions include dietary modification, stopping smoking, avoiding excessive alcohol intake, regular weight bearing, balance restoring and muscle-strengthening exercises \[[@CR26], [@CR66], [@CR67]\]. Increasing physical activity, in combination of a nutritional intervention enriched in calcium, proteins and vitamin D, has been associated with increases in BMD in postmenopausal women and improvement of muscle strength \[[@CR67]--[@CR71]\]. Whilst adopting these measures may have beneficial effects on bone health, evidence that they prevent fractures is lacking \[[@CR72]\]. Guidelines also stress the importance of taking measures to prevent falls. However, although fall prevention programmes have been shown to reduce the frequency of falls, the majority of studies in elderly subjects have failed to show fracture reduction \[[@CR73], [@CR74]\].

Pharmacological treatments {#Sec6}
--------------------------

Current pharmaceutical therapies for osteoporosis have been shown to increase femoral neck and/or total hip aBMD and, for some treatments, to reduce hip fracture risk. Across all placebo-controlled trials involving all sorts of osteoporosis drugs, hip BMD gain explains near to 60% of hip fracture reduction \[[@CR75]\]. However, comparison between medications is difficult because of largely different fracture risk in the studied populations.

Alendronate, risedronate, zoledronic acid and denosumab have all been shown to significantly decrease the risk of hip fracture by approximately 40--50% in preplanned intention to treat analyses \[[@CR76]--[@CR81]\]. This percentage reduction can be considered as a benchmark against which to compare new drug efficacy or interventions.

### Alendronate {#FPar1}

A meta-analysis of 6 randomised controlled trials in 6804 women with T-scores ≤−2.5 treated with alendronate demonstrated a 55% risk reduction in hip fractures \[[@CR81]\].

### Risedronate {#FPar2}

The HIP study evaluated 9331 women into two groups; one group had diagnosed osteoporosis, and the other had osteopenia but were considered to be at high risk of hip fracture, since being older than 80 years and presenting non-skeletal risk factors including poor gait and propensity to falls. The incidence of hip fracture amongst all women assigned to receive risedronate was 2.8% compared to 3.9% amongst placebo-treated women (corresponding to a 28% reduction). In the women with osteoporosis, the incidence was 1.9% in risedronate treated vs. 3.2% in placebo treated (40% reduction) \[[@CR80]\]. However, the protective effects for hip fracture with risedronate were not significant in women aged 80 years and older, who were not selected on the base of BMD but purportedly on their risk of falling, as compared to younger patients \[[@CR80]\].

### Zoledronic acid {#FPar3}

The Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly (HORIZON) trial enrolled 7765 postmenopausal women with osteoporosis and demonstrated a 41% reduction in hip fracture rates following 3 years of zoledronic acid treatment when compared to placebo \[[@CR76]\].

Furthermore, the risk of a second hip fracture was assessed; the 30% reduction in the risk of a second hip fracture did not reach the level of statistical significance \[[@CR82]\].

The lack of evidence for hip fracture reduction in women aged 75 years and older in the two HORIZON studies, as evidenced by a pooled analysis, might raise the point that recurrent falls are the most prominent mechanism for hip fracture in this population \[[@CR83]\]. Alternatively, that the level of hip bone fragility at that age cannot easily be reversed in just few years of pharmacological therapy.

### Denosumab {#FPar4}

The FREEDOM trial evaluated 7808 patients who received subcutaneous injections of either denosumab or placebo once every 6 months for 3 years. Denosumab treatment resulted in a 40% reduction of the incidence of hip fractures \[[@CR78]\], and increased cortical thickness at the hip and femur \[[@CR84]\], as well as improving determinants of structure using FEA and strength \[[@CR85]\]. Moreover, in a preplanned subgroup analysis in high-risk patients, hip fracture risk reduction in 75+ years old reached 62%.

### Teriparatide {#FPar5}

In a trial of 1637 postmenopausal women with osteoporosis, 20 and 40 μg of teriparatide daily subcutaneously were shown to reduce the incidence of new non-vertebral fragility fractures (NVFs) by 35 to 53% \[[@CR86]\]. Hip fractures were not reduced, but there were less than 1% of women with a hip fracture in this 18-month trial. In a review, Eriksen et al. \[[@CR87]\] suggest potential benefits of teriparatide on hip fracture risk.

In a study conducted on over 4000 patients (the Direct Assessment of non-vertebral fractures in Community Experience (DANCE) study), the incidence rate of NVF was beyond 6 months of treatment \[[@CR88]\].

In the European Forsteo Observational Study (EFOS), there was a 47% decrease in the odds of fracture in the last 6-month period of the 18-month trial. The NVF rates were significantly decreased between the first and the last 6-month period of treatment \[[@CR89]\].

### Strontium ranelate {#FPar6}

The Treatment of Peripheral Osteoporosis (TROPOS) study evaluated the effects of strontium ranelate in 5091 postmenopausal women with osteoporosis. The trial demonstrated a 36% risk reduction for hip fracture in a post hoc analysis subgroup (\>74 years of age and osteoporosis) over 3 years \[[@CR90]\].

### Odanacatib (investigational drug) {#FPar7}

In a phase III long-term trial conducted on more than 16,000 postmenopausal women with prior vertebral fracture, odanacatib, an investigational cathepsin K inhibitor, showed a 47% relative reduction in hip fractures \[[@CR91]\].

### Abaloparatide (investigational drug) {#FPar8}

Abaloparatide is a 34 amino acid peptide with 71% homology with PTHrP (1--34) and 41% homology with PTH (1--34) that has been developed for subcutaneous delivery in the treatment of osteoporosis. A phase III, randomised controlled trial, "ACTIVE," in a cohort of ambulatory postmenopausal female patients with osteoporosis evaluated the effect of abaloparatide-SC (80 μg daily) on fracture risk. The number of hip fractures was too small (*n* = 3) to allow any analysis, but non-vertebral fractures were significantly reduced by 43% \[[@CR92]\].

Number needed to treat {#Sec7}
----------------------

The number of patients needed to treat (NNT) over a period of 3 years to prevent one hip fracture varies between 48 for strontium ranelate and 200 for denosumab. NNT amounts to 91 for alendronate, risedronate and zoledronic acid \[[@CR93]\]. The NNT does not allow one to make any comparison between the various agents since it is mainly determined by the absolute risk, i.e. osteoporosis severity and clinical risk factors, in the placebo group. Nevertheless it indicates how many women at high risk of hip fractures---as included in those trials---would need to be exposed to some sort of invasive procedure (see below) to eventually prevent a hip fracture, in the event that a local form of therapy was to be developed.

Current challenges {#Sec8}
==================

Poor adherence {#Sec9}
--------------

Current treatments reduce hip fracture risk by up to 50% \[[@CR94]\]. In the 'real-world' setting, this residual risk is amplified by poor adherence \[[@CR95]\].

Whilst some regimens are convenient, particularly the injectable 6-month and 1-year forms, patient compliance to osteoporosis medications is poor and often below 50% after 1 year. Up to 60% of patients who take a once-weekly bisphosphonate and nearly 80% of those who take a once-daily bisphosphonate discontinue treatment within a year \[[@CR96]\].

Lack of adherence may arise from side effects from the medications (e.g. gastrointestinal irritation) or fear of rare adverse events (e.g. atypical femoral fractures, osteonecrosis of the jaw) \[[@CR97]--[@CR99]\]. It could lead to a marked decrease in antifracture efficacy of the prescribed treatments. Under-prescription of efficacious drugs by caregivers despite markedly elevated fracture risk should also be mentioned.

Onset of fracture risk reduction {#Sec10}
--------------------------------

Several studies have suggested that there is a lag time between the onset of treatment with bisphosphonates and fracture risk reduction. For example, for zoledronic acid, after the first hip fracture, the 30% reduction in the second hip fracture was evident after 16 months of treatment \[[@CR76], [@CR78], [@CR100], [@CR101]\]. For denosumab, the incidence curves appeared to diverge by about 9 months \[[@CR78]\]. The study of the onset of effect is problematic due to the low number of outcome events but, if true, has implications for patient care. Furthermore, the onset of action of different medications in different study populations can barely be compared, since a higher risk of fracture in the population under study is associated with an earlier achievement of statistical significance.

These considerations may indicate a need for early efficacious therapeutic options for those patients at imminent and very high risk of hip fracture. This would be particularly relevant following a first hip fracture. Indeed, the relative risk of re-fracture increases rapidly following a fracture and is maximal in the first year. To address these unmet needs, a specific subtype of patients that would benefit from additional approaches, including surgical preventive bone enhancement, may need to be identified (Fig. [3](#Fig3){ref-type="fig"}). Nevertheless, the risk of second fracture persists 10 years after the first one; therefore, secondary prevention should continue beyond an early postfracture period \[[@CR22], [@CR27], [@CR29]\].Fig. 3Levels of fracture risk in osteoporosis and their management

Possible role of orthopaedic interventions to strengthen bone {#Sec11}
=============================================================

In addition to systemic treatments, procedures developed for fracture immobilisation or for filling up local bone defect (e.g. bone tumours/cysts, hemangioma, avascular necrosis) have been proposed to strengthen fragile bone, particularly proximal femur, prior to fracture occurrence \[[@CR102]\]. Techniques are prophylactic nailing, femoroplasty with cement and bone grafting with osteoconductive or osteoinductive materials (Table [1](#Tab1){ref-type="table"}) \[[@CR103]\]. Like for most of the systemic therapies, these approaches do not correct the microstructural alterations. Further studies are required to identify indications and to get registration.Table 1Materials and properties of bone graft substitutes used in orthopaedicsPropertiesMaterialsCementSynthetic bone graftsAutograftPMMAOsteoconductiveOsteoinductiveAutogenousOsteoconductive (provides a scaffold for the bone to grow inside)×√√ or ×^a^√Osteoinductive (initiates bone formation)××√√Osteogenic (comprises cells in the scaffold so bone formation can start from within the graft)×××√*Source*: \[[@CR103]\]^a^Depends on carrier

The main target for preventive orthopaedic surgery is the frail oldest old, at markedly elevated risk of fracture, who is the most likely to benefit from fracture prevention. This type of patients is also the most susceptible to present co-morbidities and to develop presurgery and postsurgery medical complications. In addition, anaesthesia's risks should also be integrated into a risk/benefit assessment with quality of remaining life years as the outcome.

Prophylactic nailing {#Sec12}
--------------------

To stabilise incomplete femoral atypical fractures, prophylactic nailing has been recommended \[[@CR104]\]. Such a prophylactic nailing for highly fragile osteoporotic hips is not currently performed in clinical practice \[[@CR104]\]. In a randomised controlled trial, contralateral hip fixation using a hydroxy-apatite-coated titanium tubular screw was evaluated on the risk of recurrent fracture \[[@CR105]\]. Although the feasibility and safety of the procedure were confirmed, the results were not conclusive since no contralateral hip fracture occurred over the 16-month follow-up. There is a device called Y-STRUT®, which is indicated for contralateral percutaneous internal fixation of proximal femur in patients with a low-energy pertrochanteric fracture. This device is implanted during the same anaesthesia \[[@CR106]\]. The implant consists of two interlocking peek rods linked with surgical cement (polymethylmethacrylate (PMMA)). The loadings until failure of cadaver specimens with this implant showed increased both fracture load (+18%) and energy to fracture (+32%) as compared to contralateral femur. However, periprosthetic fracture risk should be taken into consideration in a careful benefit-risk and cost-effectiveness analysis for any new local procedure aimed at preventing hip fractures \[[@CR107]\]. Indeed, prophylactic fixation with a cephalomedullary nail was not found to be cost-effective in elderly women with hip fracture \[[@CR108]\]. However, the case may differ in selected patients.

Bone grafting {#Sec13}
-------------

Bone graft materials are useful in situations where a large volume defect needs to be refilled and also when the regenerative process is compromised (avascular necrosis, atrophic non-union). Autologous bone grafts from the iliac crest will not be reviewed here, as the duration of healing, the potential risks and complications associated with this technique are not compatible with the target population of elderly frail osteoporotic patients that require a rapid increase in bone strength \[[@CR109]--[@CR111]\].

Femoroplasty (cement augmentation) {#Sec14}
----------------------------------

Femoroplasty is a procedure in which cement, usually PMMA, is injected into an osteoporotic proximal femur. This technique has been only evaluated to date in cadaver or animals. The results showed 30--80% improvement in bone strength, the results being volume dependent (cement augmentations of 20 to 40 ml) and location dependent \[[@CR112]--[@CR114]\].

The major drawback of this procedure is the exothermic material properties of PMMA (temperature increases from +18 to +30 °C) that can cause osteonecrosis when a large volume of cement is injected \[[@CR114]\].

As a consequence, Beckman et al. developed a procedure where an 8-mm perforation is drilled in cadaver femurs and 8 to 18 ml of cement is injected. With this approach, the increase in fracture load (peak load to failure) was of lower magnitude (+23--35%) \[[@CR115]\]. In vitro verification of femoroplasty with CT imaging to improve the procedure in terms of cement distribution and location indicated an increase in the yield load of +33% vs. control osteoporotic femora, for a cement volume of 9.5 ± 1.7 ml \[[@CR116]\]. This 33% improvement in yield load, thereby reaching a value of 3000 N, by cement injection could be considered as a benchmark for the development of future interventions.

A study compared femoral augmentation using steel spirals or cement-based femoroplasty \[[@CR117]\]. Both metal implant and cement augmentation improved hip mechanical properties when the load was applied on the greater trochanter. Both procedures are simple, reproducible and minimally invasive. Some studies on femoroplasty failed however to detect changes in biomechanical properties. Comparing cement-based femoroplasty to a minimally invasive fixation using the blade of a proximal femur nail (PFNA^™^ Depuy Synthès), the authors concluded that limited V-shaped PMMA augmentation and PFNA blade insertion did not show any improvement in failure load nor energy to failure \[[@CR118]\]. In contrast to Beckman et al. \[[@CR115]\], another study concluded that 15 ml of cement was not sufficient to augment the proximal femur and to provide biomechanical advantage \[[@CR119]\].

It is possible that femoroplasty may be associated with the occurrence of subtrochanteric fractures, fat embolism, circulatory damage and stress concentration \[[@CR114], [@CR115], [@CR119]\]. The impact of femoroplasty on femur vascularisation is still unknown. Thus, clinical validation of the technique is a research priority.

Bone grafts with osteoconductive or osteoinductive materials {#Sec15}
------------------------------------------------------------

Some bone graft substitutes, such as calcium phosphate bone cements, resorbable polymers or allograft, can also serve as an intra-osseous scaffold for delivery of bone anabolic agents capable of stimulating bone formation and augmenting bone mass \[[@CR120]\]. Synthetic bone grafts are mainly made of calcium-phosphate (e.g. hydroxyapatite and tricalcium phosphate), bioglass and calcium sulphate \[[@CR121]\]. Such materials can be used as carriers for growth factors to enhance bone graft efficacy, drugs (bisphosphonates) or ions (strontium) to promote osteoblast proliferation \[[@CR122]--[@CR126]\]. Local administration of bone morphogenetic protein (rhBMP-2, rh-BMP-7) is another example of osteoanabolic substances use. However, the implant procedure may be accompanied by an intense first phase of bone resorption when a high dose of BMPs is used, which may preclude its use in osteoporosis \[[@CR127], [@CR128]\].

Presently, the bone graft administration field is very wide (with orthopaedics, traumatology, maxilla-facial/dental applications), with the spine being its largest application site (45% of procedures). The main drawback of bone graft substitutes is that they are usually used to fill a defect (e.g. left by the extraction of a tumour or a cyst). In osteoporosis, the administration of osteoconductive or osteoinductive materials requires fluid material to avoid injection under high pressure in the trabecular bone network of the proximal femur.

Conclusions {#Sec16}
===========

The prevention of hip fractures, the most devastating complication of osteoporosis, remains a challenge, considering that only a minority of high-risk patients, including patients with a recent hip fracture who carry at least a 10% early risk of contralateral fracture, are actually given osteoporosis therapy; that the efficacy of the most potent osteoporosis drugs to prevent hip fractures is at best 50% after more than 12--18 months of therapy; and that 50% or more of the patients may have discontinued osteoporosis therapy by then. Hence, complementary approaches to immediately prevent hip fractures in patients at very high risk may need to be developed, including surgical approaches.

Some new materials are currently being developed that are synthetic, resorbable, osteoconductive and osteoinductive materials, with the aim of locally strengthening weak bone structure, e.g. hip, to fill a gap in the management of elderly patients with an increased imminent risk of hip fracture. However, the acceptability of a minimal but still invasive procedure in frail patients added to the need to use clear surrogate markers for bone strength improvement, together with the identification of high risk most likely to benefit from the procedure, highlights the difficulty of clinical studies aimed at demonstrating the benefits and safety profile of such innovative devices. Intervention thresholds remain to be established in a more global context of an encompassing risk-benefit analysis. Overall, the benefits should be in line with the risks.

An erratum to this article is available at <http://dx.doi.org/10.1007/s11657-017-0319-2>.
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